FDA advisers urge approval of Exubera, Pfizer promises monitoring plan

09/9/2005 | CNNMoney · Wall Street Journal, The

An FDA advisory panel recommended the agency give its approval to an insulin inhalant, Exubera, developed by Pfizer, Nektar Therapeutics and Sanofi-Aventis for diabetics. Pfizer said it was ready to begin a patient-monitoring plan to track the safety of the product, considered by the industry to have sales possibilities of $2 billion a year.

View Full Article in:

CNNMoney · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL